SG/CALL/NOVO-NORDISK B/1180/0.1/21.03.25

SG/CALL/NOVO-NORDISK B/1180/0.1/21.03.25 Stock

DE000SW7ZJG1

Real-time Boerse Frankfurt Warrants 07:27:52 2024-06-03 EDT
0.51 ^EUR	-7.27%

1 month

-24.66%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/CALL/NOVO-NORDISK B/1180/0.1/21.03.25

Latest news about NOVO NORDISK A/S

Structure Therapeutics' obesity drug meets main goal in mid-stage study	07:55am	RE
JPMorgan European G&I raises dividend after outperforming benchmark	06:08am	AN
Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment	05-31	MT
Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs	05-30	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.51	-7.27%
24-05-31	0.55	+1.85%
24-05-30	0.54	+3.85%
24-05-29	0.52	-10.34%
24-05-28	0.58	-15.94%

Real-time Boerse Frankfurt Warrants

Last update June 03, 2024 at 07:27 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SW7ZJG
ISIN	DE000SW7ZJG1
Date issued	2024-03-20
Strike	1,180 kr
Maturity	2025-03-21 (291 Days)
Parity	10 : 1
Emission price	0.91 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.92 €
Lowest since issue	0.5 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	23.78x
Moneyness	0.7748
Difference Strike	262.8 kr
Difference Strike %	+22.27%
Spread	0.01 €
Spread %	1.92%
Intrinsic value	0.000000
Present value	0.5250

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company